Moderator: Prof. Dr. D. Tilki (DE)
Presenters: Prof. B. Tombal (BE) and Prof. Dr. H.G. Van Der Poel (NL)
PARP inhibitors in prostate cancer treatment is still a relatively new topic for most urologists. With this PARPi curriculum we offer urologists an educational programme addressing the following learning objectives:
- Understanding the rationale for PARPi combinations as potential PCa treatments
- Getting more insights on patient selection/identification for potential treatment with PARPi combinations
- Learn the latest developments by discussing ongoing clinical trial design exploring PARPi combinations in prostate cancer
In a series of webinars we will tackle its role in prostate cancer treatment, discussing the latest evidence and a practical guide in how to use it in your daily practice.